Delivery Order SPE2DB22D3016-SPE2DB26FAAJ3
Award Date 10/21/25
Potential Completion Date 10/22/25
Potential Value $8.4K
Federal Agency
Awardee
Ultimate Awardee
Not listed PSC Category
Federal Contract Vehicle
- Not listed
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a $2,527.44 delivery order on September 19, 2025, for the supply of HEPLISAV-B 20 MCG/0.5 ML syringes. This is a firm fixed-price, non-set-aside contract with a completion date of September 22, 2025, with performance occurring at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, received a $6,318.60 firm fixed-price delivery order from the Defense Logistics Agency (DLA) on August 22, 2025, for HEPLISAV-B 20 MCG/0.5 ML syringes. This award was made without a set-aside designation, indicating it was competitively awarded. The delivery order is scheduled for completion by August 25, 2025, with performance to be executed at the company's Conshohocken facility....
- The Defense Logistics Agency awarded a $143,366.66 delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on September 9, 2025, with an ultimate completion date of September 10, 2025. This is a firm fixed price, competitively awarded contract with no set-aside designation. The contract is performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes valued at $1,684.96, with an ultimate completion date of June 25, 2025. This is a firm fixed price delivery order with no set-aside designation, representing a competitive award to the major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania. The product will be performed at AmerisourceBergen's Conshohocken location. HEPLISAV-B is a recombinant...
- This is a delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corporation's Corporate Office Division. The $79,925.16 firm fixed-price contract is for the delivery of the HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML vaccine. The award has an ultimate completion date of August 20, 2024. AmerisourceBergen, a major pharmaceutical distributor, has been awarded numerous federal contracts and Indefinite Delivery Contracts (IDCs) to supply a wide range of medical commodities,...
- This is a $1,684.96 firm fixed-price delivery order awarded by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, which is a hepatitis B vaccine. The award has an ultimate completion date of March 19, 2025. AmerisourceBergen holds a significant $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which...
- The Defense Logistics Agency awarded a delivery order valued at $2,467.15 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 mcg/0.5 ml syringes on August 7, 2025, with completion expected by August 8, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. HEPLISAV-B is a recombinant hepatitis B vaccine indicated for use in adult populations, representing part...
- The Defense Logistics Agency awarded a delivery order valued at $15,164.64 to AmerisourceBergen Drug Corp for HEPLISAV-B 20 MCG/0.5 ML syringes on July 22, 2025, with an ultimate completion date of July 23, 2025. The contract utilizes firm fixed pricing with no set-aside designation, indicating competitive award. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving as a critical federal medical procurement vendor, particularly...
- This is a delivery order award to Amerisourcebergen Drug Corp's Corporate Office division, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The $108,006.30 firm-fixed-price contract is for the supply of HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML, a hepatitis B vaccine. The order has an ultimate completion date of August 6, 2024. Amerisourcebergen is a key supplier of pharmaceutical and medical products to various federal agencies and healthcare programs,...
- Amerisourcebergen Drug Corp, a subsidiary of the global pharmaceutical distribution company Amerisourcebergen Corporation, has been awarded a $78,864.00 firm fixed price delivery order contract by the Defense Logistics Agency (DLA) to provide HEPLISAV-B 20 MCG/0.5 ML SYRNG 0.5ML pharmaceuticals. This delivery order does not have a set-aside designation and is part of a larger indefinite delivery contract (IDC) with a potential value of $999,999,999.00 that Amerisourcebergen Drug Corp holds...